ClinicalTrials.govpublic full text
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
metastatic non small cell lung cancer, kras g12c, metastatic nsclc, sotorasib, lenvatinib, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 859639
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.